Terumo (OTCMKTS:TRUMY) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS

by · The Markets Daily

Terumo (OTCMKTS:TRUMY – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06), Zacks reports. Terumo had a net margin of 13.83% and a return on equity of 10.44%.

Terumo Stock Down 6.5%

Shares of OTCMKTS TRUMY traded down $1.03 during midday trading on Thursday, hitting $14.75. The company’s stock had a trading volume of 22,099 shares, compared to its average volume of 233,765. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.19 and a quick ratio of 1.37. The firm has a market capitalization of $21.76 billion, a price-to-earnings ratio of 20.77 and a beta of 0.82. The business’s fifty day simple moving average is $14.83 and its two-hundred day simple moving average is $14.08. Terumo has a 1 year low of $12.08 and a 1 year high of $16.81.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on TRUMY shares. Nomura upgraded shares of Terumo from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Zacks Research upgraded shares of Terumo from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 13th. Two equities research analysts have rated the stock with a Strong Buy rating. According to MarketBeat.com, the company has a consensus rating of “Strong Buy”.

Check Out Our Latest Stock Report on Terumo

About Terumo

(Get Free Report)

Terumo Corporation is a Japan-based medical technology company that develops and manufactures products for hospitals, clinics and other healthcare providers. Founded in 1921, the company began by producing clinical thermometers and has since expanded into a broad range of medical devices and services. Terumo’s businesses include cardiovascular and vascular products, such as catheter-based devices and systems used in the treatment of heart and vascular conditions; medical care products, including infusion and injection devices; and blood and cell technologies used to collect, process and manage blood and cellular therapies.

Featured Stories